Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Watson gets rights to Synthon's biosimilar; adds to its Amgen alliance

Executive Summary

Watson Pharmaceuticals Inc. has licensed exclusive rights to Synthon BV’s (focused on generics for cancer and immune disorders) trastuzumab, being developed as a biosimilar to Roche/Genentech Inc.’s breast and gastric cancer drug Herceptin.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies